Key takeaways
Mayzent (siponimod) and Lemtrada (alemtuzumab) are both used to treat relapsing forms of multiple sclerosis (MS), but they have several key differences. Mayzent is taken orally as a daily tablet, while Lemtrada is given as an annual infusion by a healthcare provider. Mayzent requires genetic testing before starting treatment to determine the appropriate dose, whereas Lemtrada is typically reserved for those who haven't responded well to at least two other MS medications. Lemtrada has a higher risk profile, including serious autoimmune problems, infusion reactions, and a need for ongoing monitoring through a REMS program. In contrast, Mayzent's common side effects include headache and high blood pressure, and it also requires monitoring but not through a specialized program. Additionally, Both medications are available as brand name only and they both are not safe during pregnancy and require birth control measures during and after treatment.
